AbCellera, Lilly to co-develop antibody therapies for COVID-19 treatment
AbCellera and Lilly will select antibodies isolated from recovered COVID-19 patients to create antibody therapeutics for treatment and…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
13 Mar 20
AbCellera and Lilly will select antibodies isolated from recovered COVID-19 patients to create antibody therapeutics for treatment and…
26 Feb 20
The companies will work closely on the clinical development, manufacturing, and commercialization of antibodies developed by Vir Biotechnology
09 Jan 20
The partnership is aimed at exploring potential new therapies encompassing autoimmune, infectious and idiopathic disorders, using SAB’s DiversitAb…
05 Dec 19
Healthcare firm Novartis and AWS will jointly develop ‘Insight Centres’ to provide real-time visibility across the network of…
19 Nov 19
Novo Nordisk will pay $175m as upfront payment, $50m as an equity investment in Dicerna at a premium,…
05 Nov 19
Boehringer Ingelheim and Eli Lilly have been developing and commercialising Trajenta (linagliptin) and Basaglar (insulin glargine)
07 Oct 19
Cynata retains all the commercial rights to use the Cymerus MSCs in osteoarthritis and would pay up to…
25 Sep 19
Pfizer and Flatiron Health have expanded collaboration to jointly work on integrating real-world evidence for breast cancer medicines
03 Sep 19
CHEPLAPHARM has selected Clinigen to distribute Etopophos and Vepesid in Australia and New Zealand as part of its…